



CORRECTION OPEN



# Publisher Correction: Dalbavancin: novel candidate for COVID-19 treatment

Markus Hoffmann , Yeonhwa Jin and Stefan Pöhlmann 

© The Author(s) 2022

*Cell Research* (2022) 0:1; <https://doi.org/10.1038/s41422-022-00713-y>Correction to: *Cell Research* <https://doi.org/10.1038/s41422-020-00459-5>, published online 20 January 2021

The licence information was missing from this article and should have been CC-BY.

The original article has been corrected.

adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2022

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing,